Abstract
Background: Efficacy of heparin and low-molecular-weight heparins (LMWHs) in inflammatory bowel disease (IBD) treatment has been suggested. The multimatrix oral formulation MMX releases active drugs in the colon, avoiding systemic absorption. Parnaparin sodium is the LMWH chosen to be carried in the MMX formulation. Aim: To assess the safety of three different oral dosages (70, 140 and 210 mg once daily) of Parnaparin-MMX (CB-01-05) in left-sided ulcerative colitis (UC). Methods: Left-sided UC patients, with a mild-to-moderate relapse were enrolled. All patients received Parnaparin-MMX for 8 weeks. Clinical Activity Index (CAI), Disease Activity Index (DAI), Endoscopic Activity Index and IBD-QoL were assessed throughout the study. A strict clinical and laboratory follow-up, including assessment of anti-factor Xa activity, was performed. Clinical remission was defined as CAI
| Original language | English |
|---|---|
| Pages (from-to) | 581-588 |
| Number of pages | 8 |
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 28 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sep 2008 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Oral, colonic-release low-molecular-weight heparin : An initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. / Pastorelli, L.; Saibeni, S.; Spina, L.; Signorelli, C.; Celasco, G.; De Franchis, R.; Vecchi, M.
In: Alimentary Pharmacology and Therapeutics, Vol. 28, No. 5, 09.2008, p. 581-588.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral, colonic-release low-molecular-weight heparin
T2 - An initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis
AU - Pastorelli, L.
AU - Saibeni, S.
AU - Spina, L.
AU - Signorelli, C.
AU - Celasco, G.
AU - De Franchis, R.
AU - Vecchi, M.
PY - 2008/9
Y1 - 2008/9
N2 - Background: Efficacy of heparin and low-molecular-weight heparins (LMWHs) in inflammatory bowel disease (IBD) treatment has been suggested. The multimatrix oral formulation MMX releases active drugs in the colon, avoiding systemic absorption. Parnaparin sodium is the LMWH chosen to be carried in the MMX formulation. Aim: To assess the safety of three different oral dosages (70, 140 and 210 mg once daily) of Parnaparin-MMX (CB-01-05) in left-sided ulcerative colitis (UC). Methods: Left-sided UC patients, with a mild-to-moderate relapse were enrolled. All patients received Parnaparin-MMX for 8 weeks. Clinical Activity Index (CAI), Disease Activity Index (DAI), Endoscopic Activity Index and IBD-QoL were assessed throughout the study. A strict clinical and laboratory follow-up, including assessment of anti-factor Xa activity, was performed. Clinical remission was defined as CAI
AB - Background: Efficacy of heparin and low-molecular-weight heparins (LMWHs) in inflammatory bowel disease (IBD) treatment has been suggested. The multimatrix oral formulation MMX releases active drugs in the colon, avoiding systemic absorption. Parnaparin sodium is the LMWH chosen to be carried in the MMX formulation. Aim: To assess the safety of three different oral dosages (70, 140 and 210 mg once daily) of Parnaparin-MMX (CB-01-05) in left-sided ulcerative colitis (UC). Methods: Left-sided UC patients, with a mild-to-moderate relapse were enrolled. All patients received Parnaparin-MMX for 8 weeks. Clinical Activity Index (CAI), Disease Activity Index (DAI), Endoscopic Activity Index and IBD-QoL were assessed throughout the study. A strict clinical and laboratory follow-up, including assessment of anti-factor Xa activity, was performed. Clinical remission was defined as CAI
UR - http://www.scopus.com/inward/record.url?scp=48449091370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48449091370&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2008.03757.x
DO - 10.1111/j.1365-2036.2008.03757.x
M3 - Article
VL - 28
SP - 581
EP - 588
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 5
ER -